Vertex Pharmaceuticals Inc. (VRTX) Buy, Sell…

Vertex Pharmaceuticals Inc. (VRTX)

452.10

+0.47 (0.10%)

as of Jun 18, 2026, 8:50:17 pm Market Open.

35 watching

BUY

PPH, an ETF for pharma producers, is breaking out and near a record. VTX and Eli Lilly are leaders in this space and Vertex has a great product for Cystic Fibrosis therapeutics. It is growing well and not too expensive.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Jan 04/22, Up 57.9%)Stochchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with VRTX has triggered its stop at $350. To remain disciplined, we recommend covering the position at this time. This will result in a net investment gain of 44%, when combined with our previous recommendations.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Jan 04/22, Up 88.8%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with VRTX is progressing well. To remain disciplined, we recommend trailing up the stop (from $330) to $350 at this time.

BUY

They're in the MS business, so will they expand beyond MS? HE's confident they will and have some hit drugs.

PARTIAL SELL

A high-quality biopharma with a strong cystic fibrosis drug. Are trying to get into other franchises like diabetes treatments. Will do well long-run. Trades at 23x with 11% earnings growth, so you can take some profits now. Had a good run, so take some money off the table.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Jan 04/22, Up 72.5%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with VRTX is progressing well. To be disciplined, we recommend trailing up the stop (from $320) to $330 at this time.

BUY

Not too expensive. They report next week. They have good momentum and products.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Jan 04/22, Up 71.5%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with VRTX is progressing well. We now recommend to trail up the stop (from $300) to $320.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Jan 03/23, Up 57.2%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with VRTX is progressing well. We recommend trailing up the stop to $300 at this time.

BUY

New for him. Are diversifying away from Cystic Fibrosis drugs into other treatments.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Jan 04/22, Up 34.9%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with VRTX is progressing well. To remain disciplined, we recommend trailing up the stop (from $270) to $280.

TOP PICK

It is in the biotech sector which came under pressure18 months ago. The sector found a footing in June and has held well above lows while the market is selling off. In general there are great bio technologies coming to market. Specifically it is a leading producer of a Cystic Fibrosis treatment that continues to proliferate around global health care systems. It is head and shoulders over what was available previously. It is a defensive stock because earnings are not cyclical and it is growing at 25% per year as well as trading at 18X next year's earnings. With a 74 billion market cap it just made a 5 year high which is very significant. (Analysts’ price target is $310.80)

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Jan 04/22, Up 29.4%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK is progressing well. We now recommend trailing up the stop (from $245) to $270.

BUY

Bought this, adding to his healthcare holdings, a defensive sector he likes. Strong balance sheet with a deep pipeline of drugs, 20x 2023 earnings, 50% operating margins, and 5% free cash flow yield.

TOP PICK

Biotech. Dominant drug for CF treatment. Exceedingly strong growth profile, with 2022 estimate for 40% earnings growth. Working on a compound for acute pain that's not addictive. Technically way outperformed the biotech group. Now there's strength in the group and the market. No dividend. (Analysts’ price target is $307.75)

Showing 1 to 15 of 25 entries

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Vertex Pharmaceuticals Inc. (VRTX) Frequently Asked Questions

What is Vertex Pharmaceuticals Inc. stock symbol?

Vertex Pharmaceuticals Inc. is a American stock, trading under the symbol VRTX (previously VRTX-Q on Stockchase) on the NASDAQ (VRTX). It is usually referred to as NASDAQ:VRTX or VRTX

Is Vertex Pharmaceuticals Inc. a buy or a sell?

In the last year, no analyst issued a Buy, Sell, or Hold rating on VRTX (previously VRTX-Q on Stockchase) on Stockchase. Read the latest expert commentary for Vertex Pharmaceuticals Inc..

Is Vertex Pharmaceuticals Inc. a good investment or a top pick?

Vertex Pharmaceuticals Inc. was recommended as a Top Pick by David Burrows on 2022-08-11. Read the latest stock experts ratings for Vertex Pharmaceuticals Inc..

Why is Vertex Pharmaceuticals Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Vertex Pharmaceuticals Inc..

Is Vertex Pharmaceuticals Inc. worth watching?

Vertex Pharmaceuticals Inc. is followed by 35 investors on Stockchase and is a trending stock that is worth watching.

What is Vertex Pharmaceuticals Inc. stock price?

On 2026-06-18, Vertex Pharmaceuticals Inc. (VRTX) stock closed at a price of $452.10.

Most Recent Experts

Stockchase Insights

5i Research

Brian Acker, CA

Acker Finley Inc.

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

David Burrows

Barometer Capital Management

Jim Cramer - Mad Money

CNBC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Vertex Pharmaceuticals Inc. (VRTX)